Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites

被引:185
作者
Dixelius, J
Mäkinen, T
Wirzenius, M
Karkkainen, MJ
Wernstedt, C
Alitalo, K
Claesson-Welsh, L
机构
[1] Univ Uppsala, Dept Genet & Pathol, Rudbeck Lab, S-75185 Uppsala, Sweden
[2] Univ Helsinki, Biomedicum Helsinki, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland
[3] Uppsala Biomed Ctr, Ludwig Inst Canc Res, S-75124 Uppsala, Sweden
关键词
D O I
10.1074/jbc.M304499200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Vascular endothelial growth factors (VEGFs) regulate the development and growth of the blood and lymphatic vascular systems. Of the three VEGF receptors ( VEGFR), VEGFR-1 and -2 are expressed on blood vessels; VEGFR-2 is found also on lymphatic vessels. VEGFR-3 is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Although VEGFR-3 is essential for proper lymphatic development, its signal transduction mechanisms are still incompletely understood. Trans-phosphorylation of activated, dimerized receptor tyrosine kinases is known to be critical for the regulation of kinase activity and for receptor interaction with signal transduction molecules. In this study, we have identified five tyrosyl phosphorylation sites in the VEGFR-3 carboxyl-terminal tail. These sites were used both in VEGFR-3 overexpressed in 293 cells and when the endogenous VEGFR-3 was activated in lymphatic endothelial cells. Interestingly, VEGF-C stimulation of lymphatic endothelial cells also induced the formation of VEGFR-3/VEGFR-2 heterodimers, in which VEGFR-3 was phosphorylated only at three of the five sites while the two most carboxyl-terminal tyrosine residues appeared not to be accessible for the VEGFR-2 kinase. Our data suggest that the carboxyl-terminal tail of VEGFR-3 provides important regulatory tyrosine phosphorylation sites with potential signal transduction capacity and that these sites are differentially used in ligand-induced homo- and heterodimeric receptor complexes.
引用
收藏
页码:40973 / 40979
页数:7
相关论文
共 36 条
  • [21] MATSUMOTO T, 2001, SCI STKE 2001
  • [22] Modulation of VEGFR-2-mediated endothelial-cell activity by VEGF-C/VEGFR-3
    Matsumura, K
    Hirashima, M
    Ogawa, M
    Kubo, H
    Hisatsune, H
    Kondo, N
    Nishikawa, S
    Chiba, T
    Nishikawa, SI
    [J]. BLOOD, 2003, 101 (04) : 1367 - 1374
  • [23] VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors
    Mattila, MMT
    Ruohola, JK
    Karpanen, T
    Jackson, DG
    Alitalo, K
    Härkönen, PL
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2002, 98 (06) : 946 - 951
  • [24] PAJUSOLA K, 1992, CANCER RES, V52, P5738
  • [25] PAJUSOLA K, 1994, ONCOGENE, V9, P3545
  • [26] PAJUSOLA K, 1993, ONCOGENE, V8, P2931
  • [27] Partanen TA, 1999, CANCER-AM CANCER SOC, V86, P2406, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2406::AID-CNCR31>3.3.CO
  • [28] 2-5
  • [29] VEGF-C and VEGF-D expression in neuroendocrine cells and their receptor, VEGFR-3, in fenestrated blood vessels in human tissues
    Partanen, TA
    Arola, J
    Saaristo, A
    Jussila, L
    Ora, A
    Miettinen, M
    Stacker, SA
    Achen, MG
    Alitalo, K
    [J]. FASEB JOURNAL, 2000, 14 (13) : 2087 - 2096
  • [30] Lymphangiogenic gene therapy with minimal blood vascular side effects
    Saaristo, A
    Veikkola, T
    Tammela, T
    Enholm, B
    Karkkainen, MJ
    Pajusola, K
    Bueler, H
    Ylä-Herttuala, S
    Alitalo, K
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (06) : 719 - 730